realizing the "Pennies" are the place to be
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope so! As far as TDA goes, I noticed another of my pennies is showing friday's close way off from actual..... oh well
I looked at TDA too and saw .0259 - I see .0243 on a couple others
where do you see it gapping up? I show .0243 - .0249 & it closed friday at .0259.
wrong board
Nice close @ near HOD! I didn't see daytraders bailing right before the end of day/week as they sometimes do. Very encouraging for monday! Have a good weekend all!!
Chugga, chugga, chugga
That was my 5 mil., it went thru in a few seconds....
It's not a norm to publish pictures in a news release, I don't believe Mr. Cotton USED anyone. He appreciated it, tho.
mcforester, I haven't figured out how to post a snapshot of the L2 I view yet....
.0231 - .0234
Very good food for thought! (EOM)
over 65,000,000
.0009 - .001
.028 - .0285
OOOps, Chase, meant for this to be public. Let me try it again:
I think it was cool for Mr. Cotton to acknowledge and give thanks for the photo video. He seems very intouch with shareholders!
Getting close to that elusive .03
Cabo, Cabo, Cabo
.026 - .027
.025 - .0251 Nice GAP up coming!
.0245 - .0249
.024 - .0248
Not much activity yet on L2. A little early yet......
40 minutes and no messages! We're all waiting on pins and needles in anticipation of the good news!
GO CWRN!
Does this mean you bought all you want in the last hour and am ready to sell it?
huge DITTO here! lol (eom)
I just BOT almost 2 million more @ .0006 and the pena ask of .0006 didn't move - they must have alot to sell!
Excelent!!! Thx (EOM)
Hi Vianna,
Me thinks something is up too. Glad I got in yesterday, even tho it's a small position.
gap
Is your order All or None?
I think we'll see more of the same day-trader posts we saw on the last run-up. It's all part of their game. IMHO
Chugga, Chugga, Chugga....
Hi Paige.....Thx, glad to be here. Just wish something would finally happen with CDEX.
60% BUY BACK OF FLOAT will be huge! I hope management goes thru with it.
I think the MM's will shake it either way.
IMO
bigstocksnbonds,
I'm hoping to retire off of CWRN too. Either I have more shares than you, or I require less money to retire! Either way, I'm feeling more confident each and every day. I no longer worry about the minute-by-minute prices. This should take care of itself now, and it's just a matter of when.
All IMHO,
gap
Agreed, lol.....but with the action thus far this week, including today, I will be happy with a close today around .016. Back to a slow, steady climb would be better for my nerves, too.
It's a very normal pullback for how fast we climbed. Count me in on the "Haven't sold a share" group!
capnmike, More info about the Missouri State Patrol and this bust SURE would be nice. For instance, can their canine also sniff meth? Did this canine unit have with them a meth gun? If so, did they also use the meth gun on the door handles?
Thanks, Mike, for all your research....wish I had time to read it all.
gap
Press Release Source: Progen Industries Limited
Progen Buys Back PI-88 Royalty Obligation From Medigen
Tuesday January 16, 9:00 am ET
BRISBANE, Australia and TAIPEI, Taiwan, Jan. 16 /PRNewswire-FirstCall/ -- Progen Industries Limited (ASX: PGL, Nasdaq: PGLA) and Medigen Biotechnology Corporation (Medigen) today announced they have agreed terms to conclude the Agreement of Strategic Alliance (Strategic Alliance) between the two companies.
Both parties have agreed to end the Strategic Alliance to allow Progen to develop and commercialise PI-88 as rapidly as possible and with maximum flexibility. The removal of the 15% royalty obligation to Medigen means Progen now retains a much larger portion of PI-88's proceeds of commercialisation which significantly increases the value of PI-88 to the Company as it prepares for Phase III.
Key terms:
* The parties agree to end the Strategic Alliance and therefore:
* Medigen has no further obligations to conduct additional clinical
trials of PI-88 following the completion of the current Phase II HCC
trial;
* Medigen foregoes its right to earn a 15% royalty on PI-88 proceeds of
commercialisation received by Progen; and
In consideration for Medigen agreeing to end the Strategic Alliance and to compensate Medigen for its contribution to the development of PI-88, Progen has agreed to:
* Return to Medigen the 19.9% equity it holds in Medigen;
* Issue 500,000 Progen ordinary shares to Medigen on execution of the
agreement.
* Pay Medigen $A300,000 on execution of the agreement;
* Issue a further 732,600 Progen ordinary shares and pay $A2M in cash or
shares, at Progen's discretion, to Medigen on Medigen completing two
clinical milestones in relation to the current PI-88 Phase II HCC
Trial;
* Pay Medigen up to $A4M on PI-88 achieving specified clinical and
commercial milestones; and
* Issue 1,000,000 options to Medigen upon Medigen providing to Progen the
HCC Phase II Trial Final Study Report.
Mr Justus Homburg, Progen's Chief Executive Officer commented: "We believe this is an excellent opportunity to create a win-win scenario for both companies and create the greatest flexibility for PI-88 to be developed and commercially exploited."
Medigen's Chief Executive Officer, Dr Stanley Chang commented: "The alliance was struck in 2000 and at that time it was never envisaged that Progen would develop PI-88 beyond the completion of Phase II. Our continuing confidence in PI-88 is reflected in our strong desire to hold Progen equity and to agree to future milestone payments that are based on PI-88's success."
About Progen:
Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases.
Progen's three key areas of focus are:
* Clinical Development - via a focused clinical trial program involving
its two compounds PI-88 and PI-166
* Drug Discovery - projects focusing on the development of potent,
selective inhibitors of carbohydrate-protein interactions, which are
implicated in many disease processes
* Manufacturing Services - PI-88 manufacturing development and supply for
the clinical program and contract manufacturing services.
About Medigen:
Medigen Biotechnology Corporation is a Taiwanese company dedicated to the research, development and commercialization of new therapies and innovative technologies. Medigen's scientific scope is oncology, immunology and complimentary alternative medicine which are derived from the Company's R&D team's innovative proprietary Nucleic Acid Testing (NAT) Platform and clinical trial expertise.
Contact:
Linton Burns
Chief Financial Officer
Progen Industries Limited
linton.burns@progen.com.au
Ph: +61 7 3842 3333
--------------------------------------------------------------------------------
Source: Progen Industries Limited